Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth